What Analysts Are Saying About Bristol-Myers Squibb Stock

Sep 16, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low …

CouponFollow Extension

$46
OFF

What Analysts Are Saying About Bristol-Myers Squibb Stock

3 weeks from now

Sep 16, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low …

nasdaq.com

9%
OFF

What Are Wall Street Analysts' Target Price For Bristol-Myers …

3 weeks from now

2 days ago · Bristol-Myers Squibb’s stock prices soared 5.9% after the release of its impressive Q3 results on Oct. 31. Driven by the increase in sales of its Growth Portfolio and Eliquis, …

nasdaq.com

15%
OFF

Bristol-Myers Squibb Company (BMY) Stock Forecast ... - Stock …

3 weeks from now

Bristol-Myers Squibb Company (BMY) NYSE: BMY · Real-Time Price · USD. Watchlist Compare. 59.14 +0.09 (0.15%) Jan 30, 2025, 4:00 PM EST - Market closed. ... The average analyst …

stockanalysis.com

$60
OFF

Bristol-Myers Squibb Company: Target Price Consensus And …

3 weeks from now

6 days ago · Citigroup Adjusts Bristol-Myers Squibb Price Target to $60 From $55 Nov. 11: MT Analyst recommendations: Moderna, Bristol-Myers Squibb Company, Regeneron …

marketscreener.com

$61.52
OFF

Bristol-Myers Squibb (NYSE:BMY) Stock, Analyst Ratings

3 weeks from now

Bristol-Myers Squibb Co has a consensus price target of $61.52 based on the ratings of 29 analysts. The high is $85 issued by Atlantic Equities on July 28, 2023.The low is $39 issued by …

benzinga.com

$39.00
OFF

Cautious Outlook On Bristol-Myers Squibb: Sell Rating Maintained …

3 weeks from now

5 days ago · Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $39.00. Terence Flynn’s rating …

businessinsider.com

$79.25
OFF

8 Analysts Have This To Say About Bristol-Myers Squibb

3 weeks from now

Nov 18, 2022 · In the last 3 months, 8 analysts have offered 12-month price targets for Bristol-Myers Squibb. The company has an average price target of $79.25 with a high of $94.00 and …

businessinsider.com

$120
OFF

Bristol-Myers Squibb's SWOT Analysis: Stock Faces Challenges Amid ...

3 weeks from now

3 days ago · Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a …

investing.com

$59.62
OFF

Bristol Myers Squibb Reaches Analyst Target Price - Nasdaq

3 weeks from now

6 days ago · In recent trading, shares of Bristol Myers Squibb Co. (Symbol: BMY) have crossed above the average analyst 12-month target price of $59.62, changing hands for $59.67/share. …

nasdaq.com

FAQs about What Analysts Are Saying About Bristol-Myers Squibb Stock Coupon?

What are analysts' price targets for Bristol-Myers Squibb?

In the last 3 months, 6 analysts have offered 12-month price targets for Bristol-Myers Squibb. The company has an average price target of $75.83 with a high of $88.00 and a low of $60.00. Below is a summary of how these 6 analysts rated Bristol-Myers Squibb over the past 3 months. ...

Is Bristol-Myers Squibb a good stock to buy?

Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies. ...

How do analysts evaluate Bristol-Myers Squibb (BMS) stock?

Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bristol-Myers Squibb compared to the broader market. ...

What does Bristol-Myers Squibb do?

Stay up to date on Bristol-Myers Squibb analyst ratings. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. ...

What is the consensus rating for Bristol-Myers Squibb (BMY)?

The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. ...

Does Bristol-Myers Squibb have a good return on equity?

Return on Equity (ROE): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.32%, the company showcases efficient use of equity capital and strong financial health. ...